Inozyme Pharma Inc
INZY
Market Cap$324.34M
Close$
$-0.41
110.4% downside
Current Fair Value
110.4% downsideOvervalued by 110.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $324.34 Million |
|---|---|
| Enterprise Value | $328.53 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.37 |
| Beta | 1.51 |
| Outstanding Shares | 61,943,960 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.62 |
|---|---|
| PEG | -7.59 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 166.26 |
| Enterprise Value to EBIT | -3.28 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.94 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Inozyme Pharma Inc
38 employeesInozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in minera...